0001415889-24-012322.txt : 20240506 0001415889-24-012322.hdr.sgml : 20240506 20240506161559 ACCESSION NUMBER: 0001415889-24-012322 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240502 FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Posner Christopher CENTRAL INDEX KEY: 0001748265 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 24917703 MAIL ADDRESS: STREET 1: C/O CARA THERAPEUTICS, INC. STREET 2: 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL CITY: STAMFORD STATE: CT ZIP: 06902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 4 1 form4-05062024_040544.xml X0508 4 2024-05-02 0001346830 Cara Therapeutics, Inc. CARA 0001748265 Posner Christopher C/O CARA THERAPEUTICS, INC. 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 true true false false PRESIDENT AND CEO 0 Common Stock 2024-05-02 4 S 0 3936 0.75 D 176585 D This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.75 to $0.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Darren DeStefano, Attorney-in-Fact 2024-05-06